==== Front Rev Bras Ginecol Obstet Rev Bras Ginecol Obstet 10.1055/s-00030576 RBGO Gynecology & Obstetrics 0100-7203 1806-9339 Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil 32107759 10.1055/s-0040-1701457 v42n1ed Editorial The Use of Antidepressant Drugs in Climacteric Syndrome http://orcid.org/0000-0003-0312-9574 Mendes Maria Célia 1 http://orcid.org/0000-0002-4813-6404 de Sá Marcos Felipe Silva 1 1 Department of Gynecology and Obstetrics, Faculdade de Medicina, Universidade de São Paulo, Ribeirão Preto, SP, Brazil Address for correspondence Maria Célia Mendes Department of Gynecology and Obstetrics, Faculdade de Medicina, Universidade de São PauloRibeirão Preto, SPBrazilmcmendes123@gmail.com 1 2020 1 1 2020 42 1 14 https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ==== Body pmcVasomotor symptoms (VMS) or hot flashes interfere with women's quality of life and are the probable cause of sleep disorders, lack of energy, depression and tiredness in the peri- and postmenopausal period. These symptoms normally last between 2 and 10 years, with an average of 7.4 years or more.1 2 Estrogen therapy is the treatment of choice for VMS and reduces both the weekly frequency and the severity of these symptoms.3 4 For hot flashes relief, hormone treatment lasts 3 to 5 years and discontinuity may lead to recurrence in up to 50% of symptoms. On the other hand, by considering the benefits of hormone therapy for osteoporosis prevention, quality of life improvement and treatment of persistent VMS,1 there is a current trend to extend treatment until the age of 60 or 65 years old. Other drug therapies are suggested for women who do not wish to undergo estrogen therapy, usually for fear of cancer, and those with contraindications to hormone treatment, although the results of these therapies are far lower than conventional estrogen therapy. These include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Despite the inferior therapeutic results, after estrogen, these are the most used drugs for the treatment of VMS,5 and they have a very fast action (in days) in reducing hot flashes, while their antidepressant action will occur later (in weeks).6 The efficacy of this treatment is hard to evaluate, because the symptom reduction may be caused by the placebo effect of these drugs.5 Furthermore, clinical trials have no long-term follow up of patients, and most studies evaluate treatment efficacy by comparing with placebo at 4 to 12 weeks and the effect at 12 to 24 weeks after drug discontinuation.7 Both SSRIs and SNRIs bring mild to moderate improvement in symptoms and 25% to 69% reduction in hot flashes.7 8 9 For the treatment of VMS, the North America Menopause Society (NAMS) recommends paroxetine (recommendation level I), citalopram, escitalopram, venlafaxine and desvenlafaxine (level II),7 although only paroxetine has been approved by the FDA and is recommended by the American College of Obstetrics and Gynecology (ACOG).10 Regarding fluoxetine and sertraline, publications present conflicting results. Some authors argue that these medications are less effective and should be considered as a second line treatment.11 In some studies, less consistent results were observed with no statistically significant improvement in hot flashes.7 In contrast, other studies have shown a reduction in VMS,12 13 including in women with breast cancer.14 15 For these reasons, prescriptions are recommended in various services,16 and in Brazil these medications are provided for free by the Ministry of Health; hence, they are more accessible to the entire population, especially those with low purchasing power. Regarding adverse events, in a systematic review and meta-analysis published in 2014, no difference was found between the most cited side effects when comparing SSRIs with the placebo group.17 However, in several other studies, nausea, dry mouth, constipation, headache, and loss of appetite were the most frequently reported side effects with the use of SSRI/SNRI.9 18 19 Anorexia, vomiting, sexual dysfunction and insomnia19 or improved sleep were also reported with use of with paroxetine.20 21 22 Sexual dysfunction caused by SSRIs/SNRIs occurs in 32.5% to 73% of patients.23 24 According to some authors, sexual dysfunction appears to be more related to medication dose or prior depression.25 Since increased blood pressure is a side effect that may arise with the use of SNRIs, there should be caution in the use by hypertensive patients,26 and these drugs are not recommended as a first line treatment in hypertensive women.27 Nowadays, the rise in antidepressant prescriptions has been a cause for much concern worldwide. In France, the overall prevalence of prescriptions increased from 6.5% in 1999–2000 to 10.4% in 2009–201028 and in the US, from 5.84% in 1996 to 10.52% in 2005.29 In the Netherlands, the use of these drugs almost doubled between 1996 and 201230 and in the United Kingdom, from 1995 to 2011, prescriptions increased from 61.9% to 129.9% per 1,000 people-year.31 In the Netherlands, between 1996 and 2012, long-term therapy was higher among women than men (two thirds of patients) with predominance in the age group of 45 to 64 years old (45% of them).30 Selective serotonin reuptake inhibitors accounted for 52% of prescribed antidepressants, and among prescriptions in general, 47% were for depression, 23% for anxiety and ~ 25% for somatic reasons (ill defined).31 This age group covers both peri- and postmenopausal patients and it is very likely that women with vasomotor and neurovegetative symptoms characteristic of this climacteric phase were included, as anxiety and depression are often associated with hot flashes. However, the prolonged and justified use for estrogen therapy does not apply to alternative SSRI or SNRI therapy for the treatment of postmenopausal women. According to some authors, there is no conclusive evidence on the safety of antidepressants over time and their use could be more dangerous than beneficial, because it could interfere with the adaptive processes regulated by serotonin.32 The menopausal transition is an adaptive process of physiological mechanisms exerted by serotonergic neurons that are “poorly regulated” in this period, as a result of the estrogen level drop.33 After some period of hormonal instability, there is a re-adaptation of the organism to the new hypoestrogenic level, and hot flash symptoms and its repercussions on the female organism disappear. As SSRIs would be indicated to restore that balance, they should be prescribed for the shortest possible time. Therefore, some questions arise: how often do doctors offer the discontinuation of SSRI or SNRI therapy when the patient reports being well after the start of medication? Is there any control over the duration of the use of these drugs? The literature on the use of SSRIs/SNRIs in climacteric women addressing this aspect of therapy is scarce. Prolonged use of these drugs may result in ineffectiveness and possible risks. In women, especially older women, are reported higher risks for falls and fractures, stroke, suicide attempts, epileptic seizures and digestive bleeding.34 According to the literature, two thirds of outpatients with anxiety and/or depression receive treatment with psychotherapy, notably antidepressants, and these are generally used for long periods.35 In the Netherlands, 30% of patients taking antidepressants do so for at least one year; in England, half of patients and in the USA, two thirds use the medication for at least two years. Only 10% of the patients discontinue the use of these drugs each year.36 37 38 39 With regard to climacteric symptoms, information on overprescription of these drugs is not conclusive. Literature data specifically focused on the time of use and monitoring of patients receiving this treatment for climacteric VMS are frustrating. Side effects of antidepressants are underreported in the literature because they result from short-term studies. Thus, gynecologists who treat women in the climacteric period should be alert to common and persistent side effects with long-term use.40 When treating climacteric VMS, the most rational should be the use for short periods of time. When SSRIs or SNRIs are prescribed, patients should return in short time intervals for an initial assessment of therapeutic outcomes and side effects. According to international consensus, the discontinuity of antidepressants should be addressed at six to 18 months after symptom remission in case of anxiety and four to 12 months in case of depressive disorders. Unnecessary continuation of antidepressant use may result in severe side effects and harm the health of patients.34 Therefore, the recommendation is an individualized treatment based on international guidelines.41 42 For the treatment of hot flashes, unfortunately, there are no protocols that clearly determine how long SSRIs/SNRIs can or should be used in climacteric women. In the absence of evidence, patients who would eventually benefit from relief of depressive symptoms in the perimenopause may be reluctant to discontinue therapy for fear of symptom recurrence. Thus, many patients with transient episodes of depression or anxiety resulting from vasomotor phenomena receive antidepressant therapy at the beginning of treatment and prolong it beyond the necessary time, thereby becoming dependent on this therapy, which is often unnecessary and dispensable.43 44 This question is not intended to restrict the prescription of such drugs, as they are relatively safe products. In Brazil, they are not even included in the group of controlled drugs; hence, far from controlled, addictive drugs, which facilitates the use and prescription. However, the increasing use of antidepressants is worrisome, not because of the increase in indications and prescriptions for new patients, but mainly due to the prolonged use by those already taking the drug. Long-term use is advisable only in cases of chronicity or in patients who experience recurrence of symptoms after withdrawal. In such situations, and if associated with complaints of depression and anxiety, support from psychiatric specialists is advised for the benefit of the patient. Despite much controversy, SSRIs/SNRIs are yet another therapeutic option for treating hot flashes, although the results are not exciting in most patients. For women who cannot or do not wish to take estrogens, non-hormonal management, such as SSRI or SNRI is a realistic and safe therapeutic option45 as long as proper precautions are taken to avoid unnecessary prolonged use. Conflict of Interests The authors have no conflict of interests to declare. ==== Refs References 1 Pinkerton J V Sánchez Aguirre F Blake J Cosman F Hodis H N Hoffstetter S The 2017 hormone therapy position statement of The North American Menopause Society Menopause 2017 24 07 728 753. doi: 10.1097/GME.000000000000092128650869 2 Avis N E Crawford S L Greendale G Bromberger J T Everson-Rose S A Gold E B Duration of menopausal vasomotor symptoms over the menopause transition JAMA Intern Med 2015 175 04 531 539. doi: 10.1001/jamainternmed.2014.806325686030 3 Santen R J Allred D C Ardoin S P Archer D F Boyd N Braunstein G D Postmenopausal hormone therapy: an Endocrine Society scientific statement J Clin Endocrinol Metab 2010 95 07 01 s1 s66. doi: 10.1210/jc.2009-250920566620 4 Maclennan A H Broadbent J L Lester S Moore V Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes Cochrane Database Syst Rev 2004 04 CD002978. doi: 10.1002/14651858.CD002978.pub215495039 5 Santen R J Loprinzi C L Casper R F Menopausal hot flashes [Internet] UpToDate; 2016 [2019 May 12]. Available from: https://www.uptodate.com/contents/menopausal-hot-flashes 6 Freeman E W Guthrie K A Caan B Sternfeld B Cohen L S Joffe H Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial JAMA 2011 305 03 267 274. doi: 10.1001/jama.2010.201621245182 7 [No authors listed]. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Menopause 2015 22 11 1155 1172, quiz 1173–1174. doi: 10.1097/GME.000000000000054626382310 8 Stearns V Ullmer L López J F Smith Y Isaacs C Hayes D Hot flushes Lancet 2002 360 (9348):1851 1861. doi: 10.1016/s0140-6736(02)11774-012480376 9 Wiśniewska I Jochymek B Lenart-Lipińska M Chabowski M The pharmacological and hormonal therapy of hot flushes in breast cancer survivors Breast Cancer 2016 23 02 178 182. doi: 10.1007/s12282-015-0655-226498637 10 Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin N. 126: Management of gynecologic issues in women with breast cancer Obstet Gynecol 2012 119 03 666 682. doi: 10.1097/AOG.0b013e31824e12ce22353976 11 Handley A P Williams M The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review J Am Assoc Nurse Pract 2015 27 01 54 61. doi: 10.1002/2327-6924.1213724944075 12 Loprinzi C L Sloan J A Perez E A Quella S K Stella P J Mailliard J A Phase III evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 2002 20 06 1578 1583. doi: 10.1200/JCO.2002.20.6.157811896107 13 Takahashi T A Johnson K M Menopause Med Clin North Am 2015 99 03 521 534. doi: 10.1016/j.mcna.2015.01.00625841598 14 Kimmick G G Lovato J McQuellon R Robinson E Muss H B Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen Breast J 2006 12 02 114 122. doi: 10.1111/j.1075-122X.2006.00218.x16509835 15 Irarrázaval O M E Gaete G L [Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence] Rev Med Chil 2016 144 10 1326 1335. doi: 10.4067/S0034-9887201600100001328074989 16 Leon-Ferre R A Majithia N Loprinzi C L Management of hot flashes in women with breast cancer receiving ovarian function suppression Cancer Treat Rev 2017 52 82 90. doi: 10.1016/j.ctrv.2016.11.01227960127 17 Shams T Firwana B Habib F SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials J Gen Intern Med 2014 29 01 204 213. doi: 10.1007/s11606-013-2535-923888328 18 L'Espérance S Frenette S Dionne A Dionne J Y ; Comité de l'évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations Support Care Cancer 2013 21 05 1461 1474. doi: 10.1007/s00520-013-1732-823435567 19 Al-Safi Z A Santoro N Menopausal hormone therapy and menopausal symptoms Fertil Steril 2014 101 04 905 915. doi: 10.1016/j.fertnstert.2014.02.03224613533 20 Simon J A Portman D J Kaunitz A M Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials Menopause 2013 20 10 1027 1035. doi: 10.1097/GME.0b013e3182a66aa724045678 21 Pinkerton J V Joffe H Kazempour K Mekonnen H Bhaskar S Lippman J Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause Menopause 2015 22 01 50 58. doi: 10.1097/GME.000000000000031125137243 22 Capriglione S Plotti F Montera R Luvero D Lopez S Scaletta G Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial Gynecol Oncol 2016 143 03 584 588. doi: 10.1016/j.ygyno.2016.10.00627751589 23 Williams V S Baldwin D S Hogue S L Fehnel S E Hollis K A Edin H M Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey J Clin Psychiatry 2006 67 02 204 210 16566614 24 Montejo A L Llorca G Izquierdo J A Rico-Villademoros F Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction J Clin Psychiatry 2001 62 03 10 21 25 Basson R Schultz W W Sexual sequelae of general medical disorders Lancet 2007 369 (9559):409 424. doi: 10.1016/S0140-6736(07)60197-417276781 26 Stubbs C Mattingly L Crawford S A Wickersham E A Brockhaus J L McCarthy L H Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women J Okla State Med Assoc 2017 110 05 272 274 28649145 27 Heerlein A Antidepressant pharmacologic treatments Rev Chil Neuro-psiquiatr 2002 40 01 21 45. doi: 10.4067/S0717-92272002000500003 28 Olié J P Elomari F Spadone C Lépine J P [Antidepressants consumption in the global population in France] Encephale 2002 28 (5 Pt 1):411 417 12386542 29 Olfson M Marcus S C National patterns in antidepressant medication treatment Arch Gen Psychiatry 2009 66 08 848 856. doi: 10.1001/archgenpsychiatry.2009.8119652124 30 Verhaak P FM de Beurs D Spreeuwenberg P What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis BMJ Open 2019 9 02 e024051. doi: 10.1136/bmjopen-2018-024051 31 Mars B Heron J Kessler D Davies N M Martin R M Thomas K H Gunnell D Influences on antidepressant prescribing trends in the UK: 1995-2011 Soc Psychiatry Psychiatr Epidemiol 2017 52 02 193 200. doi: 10.1007/s00127-016-1306-427885400 32 Andrews P W Thomson J A Jr Amstadter A Neale M C Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good Front Psychol 2012 3 117. doi: 10.3389/fpsyg.2012.0011722536191 33 Stearns V Beebe K L Iyengar M Dube E Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial JAMA 2003 289 21 2827 2834. doi: 10.1001/jama.289.21.282712783913 34 Coupland C Dhiman P Morriss R Arthur A Barton G Hippisley-Cox J Antidepressant use and risk of adverse outcomes in older people: population based cohort study BMJ 2011 343 d4551. doi: 10.1136/bmj.d455121810886 35 Alonso J Angermeyer M C Bernert S Bruffaerts R Brugha T S Bryson H Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project Acta Psychiatr Scand Suppl 2004 420 47 54. doi: 10.1111/j.1600-0047.2004.00330.x15128387 36 Meijer W EE Heerdink E R Leufkens H GM Herings R MC Egberts A C Nolen W A Incidence and determinants of long-term use of antidepressants Eur J Clin Pharmacol 2004 60 01 57 61. doi: 10.1007/s00228-004-0726-314985889 37 Johnson C F Macdonald H J Atkinson P Buchanan A I Downes N Dougall N Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study Br J Gen Pract 2012 62 604 e773 e779. doi: 10.3399/bjgp12X65830423211181 38 Petty D R House A Knapp P Raynor T Zermansky A Prevalence, duration and indications for prescribing of antidepressants in primary care Age Ageing 2006 35 05 523 526. doi: 10.1093/ageing/afl02316690637 39 Mojtabai R Olfson M National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey J Clin Psychiatry 2014 75 02 169 177. doi: 10.4088/JCP.13m0844324345349 40 Bet P M Hugtenburg J G Penninx B W Hoogendijk W J Side effects of antidepressants during long-term use in a naturalistic setting Eur Neuropsychopharmacol 2013 23 11 1443 1451. doi: 10.1016/j.euroneuro.2013.05.00123726508 41 Bandelow B Zohar J Hollander E Kasper S Möller H J ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision World J Biol Psychiatry 2008 9 04 248 312. doi: 10.1080/1562297080246580718949648 42 Cleare A Pariante C M Young A H Anderson I M Christmas D Cowen P J Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines J Psychopharmacol 2015 29 05 459 525. doi: 10.1177/026988111558109325969470 43 Johnson C F Williams B MacGillivray S A Dougall N J Maxwell M ‘Doing the right thing’: factors influencing GP prescribing of antidepressants and prescribed doses BMC Fam Pract 2017 18 01 72. doi: 10.1186/s12875-017-0643-z28623894 44 Bosman R C Huijbregts K M Verhaak P F Ruhé H G van Marwijk H W van Balkom A J Batelaan N M Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care Br J Gen Pract 2016 66 651 e708 e719. doi: 10.3399/bjgp16X68664127528709 45 Mintziori G Lambrinoudaki I Goulis D G Ceausu I Depypere H Erel C T EMAS position statement: non-hormonal management of menopausal vasomotor symptoms Maturitas 2015 81 03 410 413. doi: 10.1016/j.maturitas.2015.04.00925982505